Royal Bank of Canada Increases Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $330.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective lifted by Royal Bank of Canada from $310.00 to ...
Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster
Alnylam Pharmaceuticals gains FDA approval for Amvuttra in ATTR-CM, boosting revenue prospects. Click here to read an ...
Alnylam Pharmaceuticals (NasdaqGS:ALNY) Sees 17% Weekly Gain As Vutrisiran Faces FDA Decision
Alnylam Pharmaceuticals (NasdaqGS:ALNY) saw a 17% price increase over the past week, likely influenced by its recent announcements and market trends. The company's R&D progress showcase on February 25 ...
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $390.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target increased by Canaccord Genuity Group from $385.00 to $390.00 in a report issued on Friday,Benzinga reports. The brokerage ...
pharmaphorum3d
Alnylam joins three-way contest in ATTR cardiomyopathy
Alnylam has the FDA approval it sought for Amvuttra in a form of cardiomyopathy associated with rare disease ATTR amyloidosis ...
American Association of Individual Investors3d
Why Alnylam Pharmaceuticals, Inc.’s (ALNY) Stock Is Up 11.75%
Alnylam Pharmaceuticals, Inc.’s ALNY share price has surged by 11.75%, which has investors questioning if this is right time ...
Alnylam trading halted, news pending
EDT Alnylam (ALNY) trading halted, news pendingLight Up your Portfolio with Spark:Easily identify stocks' risks and opportunities.
Fierce Pharma3d
Alnylam's Amvuttra wins key approval in ATTR-CM, teeing up showdown with Pfizer
Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA ...